Abstract
PROSPER study reveals reduction in bed days per hospitalisation and decreased risk of mortality for patients observed on rifaximin-alpha 550mg compared to a cohort on standard of care
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
